The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine

References

• Siu AL; US Preventive Services Task Force (USPSTF). Screening for depression in adults – US Preventive Services Task Force recommendation statement. JAMA 2016;315:380-7
   PubMed Web of Science ®Google Scholar
• Burke L. The impact of maternal depression on familial relationships. Int Rev Psychiatry 2003;15:243-55
   PubMed Web of Science ®Google Scholar
• Epstein NB, Baldwin LM, Bishop DS. The McMaster family assessment device. J Marital Fam Ther 1983;9:171-80
   PubMed Web of Science ®Google Scholar
• Hinchliffe M, Hooper D, Roberts FJ, et al. A study of the interaction between depressed patients and their spouses. Br J Psychiatry 1975;126:164-72
   PubMed Web of Science ®Google Scholar
• Keitner GI, Miller IW. Family functioning and major depression: an overview. Am J Psychiatry 1990;147:1128-37
   PubMed Web of Science ®Google Scholar
• Miller IW, Kabacoff RI, Epstein NB, et al. The development of a clinical rating scale for the McMaster Model of Family Functioning. Fam Process 1994;33:53-69
   PubMed Web of Science ®Google Scholar
• Timko C, Cronkite RC, Swindle R, et al. Functioning status of adult children of depressed parents: a 23-year follow-up. Psychol Med 2008;38:343-52
   PubMed Web of Science ®Google Scholar
• Weissman MM, Wickramaratne P, Nomura Y, et al. Offspring of depressed parents: 20 years later. Am J Psychiatry 2006;163:1001-8
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims, 2009. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf [Last accessed 27 July 2016]
   Google Scholar
• DiBenedetti DB, Danchenko N, François C, et al. Development of a family functioning scale for major depressive disorder. Curr Med Res Opin 2012;28:1-11
   Web of Science ®Google Scholar
• Williams V, François C, Danchenko N, et al. Psychometric validation of the Depression and Family Functioning Scale. Curr Med Res Opin 2016;32:639-50
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. A randomized, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol Clin Exp 2014;29:470-82
   PubMed Web of Science ®Google Scholar
• Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54:3206-21
   PubMed Web of Science ®Google Scholar
• Westrich L, Pehrson A, Zhong H, et al. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract 2012;16(Suppl 1):47
   Google Scholar
• Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active-reference study of Lu AA21004 in patients with major depressive disorder (MDD). Int J Neuropsychopharmacol 2012;15:589-600
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012;22:482-91
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012;26:1408-16
   PubMed Web of Science ®Google Scholar
• Boulenger J-P, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebocontrolled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014;29:138-49
   Google Scholar
• Henigsberg N, Mahableshwarkar A, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012;73:953-9
   PubMed Web of Science ®Google Scholar
• Jacobsen PL, Mahableshwarkar AR, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Poster NR9-06 presented at the 166th Annual Meeting of the APA, San Francisco, CA, USA, 2013
   Google Scholar
• Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27:215-23
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar A, Jacobsen PL, Serenko M, et al. A duloxetine-referenced fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult patients with MDD. Poster NR9-01 presented at the 166th Annual Meeting of the APA, San Francisco, CA, USA, 2013
   Google Scholar
• Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013;29:217-26
   PubMed Web of Science ®Google Scholar
• Koesters M, Guaiana G, Cipriani A, et al. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013;203:179-87
   PubMed Web of Science ®Google Scholar
• Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014;348:g1888
   PubMed Web of Science ®Google Scholar
• Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. London: Wiley-Blackwell, 2012
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (fourth edition, text revision) (DSM-IV-TR). Arlington, VA: American Psychiatric Association, 2000
   Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation. Guideline for good clinical practice, 1996. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf [Last accessed 27 July 2016]
   Google Scholar
• World Medical Association. Declaration of Helsinki, 2008. Available at: http://www.wma.net/en/30publications/10policies/b3/17c.pdf [Last accessed 27 July 2016]
   Google Scholar
• Sheehan DV. The anxiety disease. New York: Scribner’s, 1983
   Google Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(Suppl 3):89-95
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:99-208
   Web of Science ®Google Scholar
• Kind P. The EuroQol instrument: an index of health-related quality of life, 2nd edn. Philadelphia: Lippincott-Raven Publishers, 1996
   Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology (United States Department of Health, Education, and Welfare Publication No. 76-338). Rockville, MD: National Institute of Mental Health, 1976:218-22
   Google Scholar
• McDowell I, Newell C. Measuring health – a guide to rating scales and questionnaires, 2nd edn. New York: Oxford University Press, 1996
   Google Scholar
• Hamilton, M. The assessment of anxiety states by rating. Br J Med Psych 1959;32:50-5
   PubMed Web of Science ®Google Scholar
• Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 1988;14:61-8
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Committee for Medicinal Products for Human Use, Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of Medicinal products. London: EMA, July 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf [Last accessed 27 July 2016]
   Google Scholar
• Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71
   PubMed Web of Science ®Google Scholar
• Beck AT, Steer RA, Ball R, et al. Comparison of Beck Depression Inventories – IA and – II in psychiatric outpatients. J Personality 1996;67:588-97
   Web of Science ®Google Scholar
• Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. J Applied Psychological Measurement 1977;1:385-401
   Web of Science ®Google Scholar
• Kohout FJ, Berkman LF, Evans DA, Cornoni-Huntley. Two shorter forms of the CES-D depression symptoms index. J Aging Health 1993;5:179-93
   PubMedGoogle Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiat 1960;3:56-62
   Web of Science ®Google Scholar
• Frank L, Matza LS, Hanlon J, et al. The patient experience of depression and remission – focus group results. J Nerv Ment Dis 2007;195:647-54
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002;59:233-9
   PubMed Web of Science ®Google Scholar